A study of salivary secretion in Parkinson's disease.
Identifieur interne : 001393 ( PubMed/Corpus ); précédent : 001392; suivant : 001394A study of salivary secretion in Parkinson's disease.
Auteurs : H. Bagheri ; C. Damase-Michel ; M. Lapeyre-Mestre ; S. Cismondo ; D. O'Connell ; J M Senard ; O. Rascol ; J L MontastrucSource :
- Clinical neuropharmacology [ 0362-5664 ]
English descriptors
- KwdEn :
- Adult, Age Factors, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Dopamine Agonists (therapeutic use), Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Prospective Studies, Salivation (drug effects), Sex Factors, Sialorrhea (drug therapy), Sialorrhea (etiology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- complications : Parkinson Disease.
- drug effects : Salivation.
- drug therapy : Parkinson Disease, Sialorrhea.
- etiology : Sialorrhea.
- Adult, Age Factors, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prospective Studies, Sex Factors.
Abstract
Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study was performed to compare the unstimulated salivary flow in 83 patients with PD (8 untreated and 75 treated with levodopa + DA agonist) and in 65 age- and sex-matched control subjects. The Mann-Whitney U-test showed a significantly lower salivary flow in treated patients with PD (535 +/- 42 mg/2 min) (p < 0.002) and de novo patients (447 +/- 141) (p < 0.03) compared to controls (834 +/- 68 mg/2 min) with no relation with age or sex. Finally, the present study of reduced salivary flow in PD suggests that complaints of hypersialorrhea are not caused by a salivary defect, but could be explained by difficulties in swallowing. The decrease in salivary flow could be explained by autonomic dysfunction in PD.
PubMed: 10442250
Links to Exploration step
pubmed:10442250Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A study of salivary secretion in Parkinson's disease.</title><author><name sortKey="Bagheri, H" sort="Bagheri, H" uniqKey="Bagheri H" first="H" last="Bagheri">H. Bagheri</name><affiliation><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, Inserm U317, Faculty of Medicine, Hôpitaux de Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Damase Michel, C" sort="Damase Michel, C" uniqKey="Damase Michel C" first="C" last="Damase-Michel">C. Damase-Michel</name></author><author><name sortKey="Lapeyre Mestre, M" sort="Lapeyre Mestre, M" uniqKey="Lapeyre Mestre M" first="M" last="Lapeyre-Mestre">M. Lapeyre-Mestre</name></author><author><name sortKey="Cismondo, S" sort="Cismondo, S" uniqKey="Cismondo S" first="S" last="Cismondo">S. Cismondo</name></author><author><name sortKey="O Connell, D" sort="O Connell, D" uniqKey="O Connell D" first="D" last="O'Connell">D. O'Connell</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1999 Jul-Aug</MedlineDate></PubDate></date><idno type="RBID">pubmed:10442250</idno><idno type="pmid">10442250</idno><idno type="wicri:Area/PubMed/Corpus">001393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001393</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A study of salivary secretion in Parkinson's disease.</title><author><name sortKey="Bagheri, H" sort="Bagheri, H" uniqKey="Bagheri H" first="H" last="Bagheri">H. Bagheri</name><affiliation><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, Inserm U317, Faculty of Medicine, Hôpitaux de Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Damase Michel, C" sort="Damase Michel, C" uniqKey="Damase Michel C" first="C" last="Damase-Michel">C. Damase-Michel</name></author><author><name sortKey="Lapeyre Mestre, M" sort="Lapeyre Mestre, M" uniqKey="Lapeyre Mestre M" first="M" last="Lapeyre-Mestre">M. Lapeyre-Mestre</name></author><author><name sortKey="Cismondo, S" sort="Cismondo, S" uniqKey="Cismondo S" first="S" last="Cismondo">S. Cismondo</name></author><author><name sortKey="O Connell, D" sort="O Connell, D" uniqKey="O Connell D" first="D" last="O'Connell">D. O'Connell</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Prospective Studies</term><term>Salivation (drug effects)</term><term>Sex Factors</term><term>Sialorrhea (drug therapy)</term><term>Sialorrhea (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Sialorrhea</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sialorrhea</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Sex Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study was performed to compare the unstimulated salivary flow in 83 patients with PD (8 untreated and 75 treated with levodopa + DA agonist) and in 65 age- and sex-matched control subjects. The Mann-Whitney U-test showed a significantly lower salivary flow in treated patients with PD (535 +/- 42 mg/2 min) (p < 0.002) and de novo patients (447 +/- 141) (p < 0.03) compared to controls (834 +/- 68 mg/2 min) with no relation with age or sex. Finally, the present study of reduced salivary flow in PD suggests that complaints of hypersialorrhea are not caused by a salivary defect, but could be explained by difficulties in swallowing. The decrease in salivary flow could be explained by autonomic dysfunction in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10442250</PMID><DateCreated><Year>1999</Year><Month>09</Month><Day>28</Day></DateCreated><DateCompleted><Year>1999</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>4</Issue><PubDate><MedlineDate>1999 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>A study of salivary secretion in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>213-5</MedlinePgn></Pagination><Abstract><AbstractText>Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study was performed to compare the unstimulated salivary flow in 83 patients with PD (8 untreated and 75 treated with levodopa + DA agonist) and in 65 age- and sex-matched control subjects. The Mann-Whitney U-test showed a significantly lower salivary flow in treated patients with PD (535 +/- 42 mg/2 min) (p < 0.002) and de novo patients (447 +/- 141) (p < 0.03) compared to controls (834 +/- 68 mg/2 min) with no relation with age or sex. Finally, the present study of reduced salivary flow in PD suggests that complaints of hypersialorrhea are not caused by a salivary defect, but could be explained by difficulties in swallowing. The decrease in salivary flow could be explained by autonomic dysfunction in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagheri</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Medical and Clinical Pharmacology, Inserm U317, Faculty of Medicine, Hôpitaux de Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damase-Michel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lapeyre-Mestre</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cismondo</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012472" MajorTopicYN="N">Salivation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012798" MajorTopicYN="N">Sialorrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10442250</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001393 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001393 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10442250
|texte= A study of salivary secretion in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10442250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |